# A Study LY2228820 for Recurrent Ovarian Cancer

> **NCT01663857** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 118 (actual)

## Conditions studied

- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer

## Interventions

- **DRUG:** LY2228820
- **DRUG:** Carboplatin
- **DRUG:** Placebo
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT01663857
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2017-05-25
- **Final completion:** 2018-05-11
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2019-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01663857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01663857, "A Study LY2228820 for Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01663857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*